Intellia Therapeutics, Inc. is 1.2x more valuable than Anbio Biotechnology by market capitalization ($1.73 B vs $1.50 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NTLA | NNNN |
|---|---|---|
| Market cap | $1.73 B | $1.50 B |
| US-listed rank | #2213 | #2317 |
| Revenue (latest FY) | $67.67M | $8.65M |
| Net income (latest FY) | -$412.69M | $6.40M |
| Net margin | -609.9% | 74.1% |
| P/E (trailing FY) | - | 234.2 |
| SEC filings | 687 | 40 |
Intellia Therapeutics, Inc. is 1.2x more valuable than Anbio Biotechnology by market capitalization ($1.73 B vs $1.50 B).
In their latest fiscal years, Intellia Therapeutics, Inc. reported $67.67M in revenue while Anbio Biotechnology reported $8.65M.
Full pages: Intellia Therapeutics, Inc. and Anbio Biotechnology, or browse the full rankings.